Cargando…

Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis

We present a systematic review and network meta-analysis (NMA) that is the precursor underpinning the Bayesian analyses that adjust for publication bias, presented in the same edition in AJT. The review assesses optimal cytoreduction for women undergoing primary advanced epithelial ovarian cancer (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryant, Andrew, Johnson, Eugenie, Grayling, Michael, Hiu, Shaun, Elattar, Ahmed, Gajjar, Ketankumar, Craig, Dawn, Vale, Luke, Naik, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal of Therapeutics 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812425/
https://www.ncbi.nlm.nih.gov/pubmed/36608071
http://dx.doi.org/10.1097/MJT.0000000000001584
_version_ 1784863723362451456
author Bryant, Andrew
Johnson, Eugenie
Grayling, Michael
Hiu, Shaun
Elattar, Ahmed
Gajjar, Ketankumar
Craig, Dawn
Vale, Luke
Naik, Raj
author_facet Bryant, Andrew
Johnson, Eugenie
Grayling, Michael
Hiu, Shaun
Elattar, Ahmed
Gajjar, Ketankumar
Craig, Dawn
Vale, Luke
Naik, Raj
author_sort Bryant, Andrew
collection PubMed
description We present a systematic review and network meta-analysis (NMA) that is the precursor underpinning the Bayesian analyses that adjust for publication bias, presented in the same edition in AJT. The review assesses optimal cytoreduction for women undergoing primary advanced epithelial ovarian cancer (EOC) surgery. AREAS OF UNCERTAINTY: To assess the impact of residual disease (RD) after primary debulking surgery in women with advanced EOC. This review explores the impact of leaving varying levels of primary debulking surgery. DATA SOURCES: We conducted a systematic review and random-effects NMA for overall survival (OS) to incorporate direct and indirect estimates of RD thresholds, including concurrent comparative, retrospective studies of ≥100 adult women (18+ years) with surgically staged advanced EOC (FIGO stage III/IV) who had confirmed histological diagnoses of ovarian cancer. Pairwise meta-analyses of all directly compared RD thresholds was previously performed before conducting this NMA, and the statistical heterogeneity of studies within each comparison was evaluated using recommended methods. THERAPEUTIC ADVANCES: Twenty-five studies (n = 20,927) were included. Analyses demonstrated the prognostic importance of complete cytoreduction to no macroscopic residual disease (NMRD), with a hazard ratio for OS of 2.0 (95% confidence interval, 1.8–2.2) for <1 cm RD threshold versus NMRD. NMRD was associated with prolonged survival across all RD thresholds. Leaving NMRD was predicted to provide longest survival (probability of being best = 99%). The results were robust to sensitivity analysis including only those studies that adjusted for extent of disease at primary surgery (hazard ratio 2.3, 95% confidence interval, 1.9–2.6). The overall certainty of evidence was moderate and statistical adjustment of effect estimates in included studies minimized bias. CONCLUSIONS: The results confirm a strong association between complete cytoreduction to NMRD and improved OS. The NMA approach forms part of the methods guidance underpinning policy making in many jurisdictions. Our analyses present an extension to the previous work in this area.
format Online
Article
Text
id pubmed-9812425
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Journal of Therapeutics
record_format MEDLINE/PubMed
spelling pubmed-98124252023-01-12 Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis Bryant, Andrew Johnson, Eugenie Grayling, Michael Hiu, Shaun Elattar, Ahmed Gajjar, Ketankumar Craig, Dawn Vale, Luke Naik, Raj Am J Ther Therapeutic Advance We present a systematic review and network meta-analysis (NMA) that is the precursor underpinning the Bayesian analyses that adjust for publication bias, presented in the same edition in AJT. The review assesses optimal cytoreduction for women undergoing primary advanced epithelial ovarian cancer (EOC) surgery. AREAS OF UNCERTAINTY: To assess the impact of residual disease (RD) after primary debulking surgery in women with advanced EOC. This review explores the impact of leaving varying levels of primary debulking surgery. DATA SOURCES: We conducted a systematic review and random-effects NMA for overall survival (OS) to incorporate direct and indirect estimates of RD thresholds, including concurrent comparative, retrospective studies of ≥100 adult women (18+ years) with surgically staged advanced EOC (FIGO stage III/IV) who had confirmed histological diagnoses of ovarian cancer. Pairwise meta-analyses of all directly compared RD thresholds was previously performed before conducting this NMA, and the statistical heterogeneity of studies within each comparison was evaluated using recommended methods. THERAPEUTIC ADVANCES: Twenty-five studies (n = 20,927) were included. Analyses demonstrated the prognostic importance of complete cytoreduction to no macroscopic residual disease (NMRD), with a hazard ratio for OS of 2.0 (95% confidence interval, 1.8–2.2) for <1 cm RD threshold versus NMRD. NMRD was associated with prolonged survival across all RD thresholds. Leaving NMRD was predicted to provide longest survival (probability of being best = 99%). The results were robust to sensitivity analysis including only those studies that adjusted for extent of disease at primary surgery (hazard ratio 2.3, 95% confidence interval, 1.9–2.6). The overall certainty of evidence was moderate and statistical adjustment of effect estimates in included studies minimized bias. CONCLUSIONS: The results confirm a strong association between complete cytoreduction to NMRD and improved OS. The NMA approach forms part of the methods guidance underpinning policy making in many jurisdictions. Our analyses present an extension to the previous work in this area. American Journal of Therapeutics 2022-12-20 /pmc/articles/PMC9812425/ /pubmed/36608071 http://dx.doi.org/10.1097/MJT.0000000000001584 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Therapeutic Advance
Bryant, Andrew
Johnson, Eugenie
Grayling, Michael
Hiu, Shaun
Elattar, Ahmed
Gajjar, Ketankumar
Craig, Dawn
Vale, Luke
Naik, Raj
Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis
title Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis
title_full Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis
title_fullStr Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis
title_full_unstemmed Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis
title_short Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis
title_sort residual disease threshold after primary surgical treatment for advanced epithelial ovarian cancer, part 1: a systematic review and network meta-analysis
topic Therapeutic Advance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812425/
https://www.ncbi.nlm.nih.gov/pubmed/36608071
http://dx.doi.org/10.1097/MJT.0000000000001584
work_keys_str_mv AT bryantandrew residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis
AT johnsoneugenie residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis
AT graylingmichael residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis
AT hiushaun residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis
AT elattarahmed residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis
AT gajjarketankumar residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis
AT craigdawn residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis
AT valeluke residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis
AT naikraj residualdiseasethresholdafterprimarysurgicaltreatmentforadvancedepithelialovariancancerpart1asystematicreviewandnetworkmetaanalysis